TY - JOUR
T1 - The risk and nature of flares in juvenile idiopathic arthritis
T2 - Results from the ReACCh-Out cohort
AU - ReACCh-Out investigators
AU - Guzman, Jaime
AU - Oen, Kiem
AU - Huber, Adam M.
AU - Duffy, Karen Watanabe
AU - Boire, Gilles
AU - Shiff, Natalie
AU - Berard, Roberta A.
AU - Levy, Deborah M.
AU - Stringer, Elizabeth
AU - Scuccimarri, Rosie
AU - Morishita, Kimberly
AU - Johnson, Nicole
AU - Cabral, David A.
AU - Rosenberg, Alan M.
AU - Larché, Maggie
AU - Dancey, Paul
AU - Petty, Ross E.
AU - Laxer, Ronald M.
AU - Silverman, Earl
AU - Miettunen, Paivi
AU - Chetaille, Anne Laure
AU - Haddad, Elie
AU - Houghton, Kristin
AU - Spiegel, Lynn
AU - Turvey, Stuart E.
AU - Schmeling, Heinrike
AU - Lang, Bianca
AU - Ellsworth, Janet
AU - Ramsey, Suzanne E.
AU - Bruns, Alessandra
AU - Roth, Johannes
AU - Campillo, Sarah
AU - Benseler, Susanne
AU - Chédeville, Gaëlle
AU - Schneider, Rayfel
AU - Tse, Shirley M.L.
AU - Bolaria, Roxana
AU - Gross, Katherine
AU - Feldman, Brian
AU - Feldman, Debbie
AU - Cameron, Bonnie
AU - Jurencak, Roman
AU - Dorval, Jean
AU - LeBlanc, Claire
AU - St. Cyr, Claire
AU - Gibbon, Michele
AU - Yeung, Rae S.M.
AU - Duffy, Ciarán M.
AU - Tucker, Lori B.
N1 - Funding Information:
This study was funded by a New Emerging Team research grant from the Canadian Institutes of Health Research (funding reference number QNT 69301). Additional funding support was provided by the Fast Foundation, Toronto, Canada.
PY - 2016/6
Y1 - 2016/6
N2 - Objective To describe probabilities and characteristics of disease flares in children with juvenile idiopathic arthritis ( JIA) and to identify clinical features associated with an increased risk of flare. Methods We studied children in the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) prospective inception cohort. A flare was defined as a recurrence of disease manifestations after attaining inactive disease and was called significant if it required intensification of treatment. Probability of first flare was calculated with Kaplan-Meier methods, and associated features were identified using Cox regression. Results 1146 children were followed up a median of 24 months after attaining inactive disease. We observed 627 first flares (54.7% of patients) with median active joint count of 1, physician global assessment (PGA) of 12 mm and duration of 27 weeks. Within a year after attaining inactive disease, the probability of flare was 42.5% (95% CI 39% to 46%) for any flare and 26.6% (24% to 30%) for a significant flare. Within a year after stopping treatment, it was 31.7% (28% to 36%) and 25.0% (21% to 29%), respectively. A maximum PGA >30 mm, maximum active joint count >4, rheumatoid factor (RF)-positive polyarthritis, antinuclear antibodies (ANA) and receiving disease-modifying antirheumatic drugs (DMARDs) or biological agents before attaining inactive disease were associated with increased risk of flare. Systemic JIA was associated with the lowest risk of flare. Conclusions In this real-practice JIA cohort, flares were frequent, usually involved a few swollen joints for an average of 6 months and 60% led to treatment intensification. Children with a severe disease course had an increased risk of flare.
AB - Objective To describe probabilities and characteristics of disease flares in children with juvenile idiopathic arthritis ( JIA) and to identify clinical features associated with an increased risk of flare. Methods We studied children in the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) prospective inception cohort. A flare was defined as a recurrence of disease manifestations after attaining inactive disease and was called significant if it required intensification of treatment. Probability of first flare was calculated with Kaplan-Meier methods, and associated features were identified using Cox regression. Results 1146 children were followed up a median of 24 months after attaining inactive disease. We observed 627 first flares (54.7% of patients) with median active joint count of 1, physician global assessment (PGA) of 12 mm and duration of 27 weeks. Within a year after attaining inactive disease, the probability of flare was 42.5% (95% CI 39% to 46%) for any flare and 26.6% (24% to 30%) for a significant flare. Within a year after stopping treatment, it was 31.7% (28% to 36%) and 25.0% (21% to 29%), respectively. A maximum PGA >30 mm, maximum active joint count >4, rheumatoid factor (RF)-positive polyarthritis, antinuclear antibodies (ANA) and receiving disease-modifying antirheumatic drugs (DMARDs) or biological agents before attaining inactive disease were associated with increased risk of flare. Systemic JIA was associated with the lowest risk of flare. Conclusions In this real-practice JIA cohort, flares were frequent, usually involved a few swollen joints for an average of 6 months and 60% led to treatment intensification. Children with a severe disease course had an increased risk of flare.
UR - http://www.scopus.com/inward/record.url?scp=84969969934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969969934&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2014-207164
DO - 10.1136/annrheumdis-2014-207164
M3 - Article
C2 - 25985972
AN - SCOPUS:84969969934
SN - 0003-4967
VL - 75
SP - 1092
EP - 1098
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 6
ER -